NCT01061788 - A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

December 19, 2018

Study Completion Date

December 19, 2018

Conditions

Advanced Solid Tumors, Non-small Cell Lung Cancer

Interventions

DRUG

AMG 479, Everolimus, Panitumumab

"Dose Escalation Cohort #, Subjects, Everolimus, AMG 479~1. 3-6 subjects, Study drug administered per dose level~2. 3-6 subjects, Study drug administered per dose level~ Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level~ Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab~3. 3-6 subjects, Study drug administered per dose level~4. 3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level~NSCLS Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level"

Trial Locations (1)

27710

Duke University Medical Center, Durham